Singh, Brahma N. "Product Development, Manufacturing, and Packaging of Solid Dosage Forms Under QbD and PAT Paradigm: DOE Case Studies for Industrial Applications." AAPS PharmSciTech 20, no. 8 (2019): 313.
Abstract
An integrated approach based on QbD and PAT provides a systematic and
innovative framework for product development, manufacturing, and quality risk management. In this context, the significance of the outcome of design of experiments (DOEs) to the
selection of the product design, robust commercial manufacturing process, design space, and
overall control strategy remains vital for the success of a drug product throughout its life
cycle. This paper aims at discussing selected recent DOE case studies conducted during QbDbased and integrated QbD/PAT-based development of solid oral formulations and process
improvement studies. The main focus of this paper is to highlight the rationales and
importance of design selection during development and applications of mathematical models
and statistical tools in analyzing DOE and PAT data for developing a design space, control
strategy, and improved process monitoring. A total of 25 case studies (includes 9 PAT
application studies) have been discussed in this paper which cover 11 manufacturing
processes commonly utilized for solid dosage forms. Two case studies relevant to selection of
packaging design for solid dosage forms are also briefly discussed to complete the scope.
Overall, for a successful modern QbD approach, it is highly important that DOEs are
conducted and analyzed in a logical sequence which involves designs that are phaseappropriate and quality-driven and facilitate both statistical and chemometric thinking at
each development stage. This approach can result into higher regulatory flexibility along with
lower economic burden during life cycle of a product, irrespective of regulatory path used
(NDA or ANDA).
for full paper see https://link.springer.com/article/10.1208/s12249-019-1515-8#citeas
"An in-line terahertz sensor system (TeraView Ltd., UK)
was developed and installed on the side of a side-vented
perforated pan coater (Premier 200, Oystar Manesty, UK).
The core tablets were placebo made from directly compressible lactose monohydrate and batch size of cores was 175 kg.
For coating, an aqueous dispersion of an enteric-coating
polymer (Acryl-EZE®) was used. "
No comments:
Post a Comment